Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 9th Preview)
-
uniQure and FDA... Sham-surgery demand fuels stock roller-coaster
uniQure’s experimental Huntington’s gene therapy AMT-130 remains at the center of an escalating regulatory standoff with the U.S. Food and Drug Administration. The FDA signaled that data from uniQure’s earlier Phase I/II external-control study are insufficient and issued a strong recommendation for a prospective, randomized, double-blind, sham-surgery-controlled trial. The agency’s public stance triggered extreme share volatility as investors reassessed approval risk and commercial forecasts. Events accelerated when the FDA’s chief medical and scientific officer at CBER, Vinay Prasad, announced he will depart at the end of April. Prasad’s tenure included high-profile rejections and reversals on gene-therapy and vaccine reviews, and his exit adds uncertainty to the agency’s review process for advanced biologics. Companies and investors are recalibrating development plans for intracranial gene therapies and weighing the operational and ethical implications of sham-surgery controls in neurosurgical trials.
-
Daraxonrasib... 47–55% ORR pushes RAS drug toward Phase 3
Revolution Medicines’ daraxonrasib (RMC-6236) produced objective response rates near 47% in a first-line cohort of RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC), according to company-reported data. The multi-selective RAS(ON) tri-complex inhibitor showed disease control rates above historic chemotherapy benchmarks and a more favorable Grade ≥3 adverse event profile compared with standard regimens. Investigators and the company are positioning daraxonrasib to advance into Phase 3 (RASolute 303), arguing the oral RAS-targeted approach could offer a chemotherapy-sparing alternative for >90% of PDAC cases driven by KRAS mutations. Progression-free and overall survival data remain immature; sponsors will need confirmatory randomized data to displace entrenched chemotherapy standards.
-
Roche, Zealand: Obesity peptide meets Phase 2 goals – weight loss under expectations
Roche and Zealand Pharma reported that petrelintide, a peptide amylin-receptor agonist, met the primary endpoints in a Phase 2 obesity study with tolerability comparable to placebo. The trial achieved statistical weight-loss goals but produced mean reductions below some analyst forecasts, prompting questions about the drug’s competitive positioning against higher-efficacy GLP-1 and dual-agonist therapies. Roche and Zealand face a crowded anti-obesity market; the readout clarifies petrelintide’s safety profile but raises commercial differentiation issues. Sponsors will need larger, longer trials and clear positioning—possibly combination strategies or niche indications—to win payer and prescriber adoption against incumbents.
-
Lenacapavir resistance pathways mapped: HIV finds new escape routes
Researchers published a Nature Communications study mapping recurrent and novel HIV-1 evolutionary pathways that confer resistance to lenacapavir, the long-acting capsid inhibitor. The team, led by Orris, Siddiqui, Tang and colleagues, identified multiple mutational trajectories the virus can adopt under drug pressure and characterized their effects on drug binding and viral fitness. The findings have immediate relevance for clinicians and drug developers deploying long-acting antiretrovirals: surveillance for emergent capsid mutations will be essential in populations receiving lenacapavir, and combination strategies or next-generation capsid-targeting chemotypes may be required to sustain durable suppression.
-
Dilution-and-delay assay... High-throughput detection exposes hidden antibiotic resistance
A Nature Communications paper from Ma and Kim introduces the dilution-and-delay (DnD) susceptibility assay, a high-resolution, high-throughput method designed to detect low-frequency or inducible antibiotic resistances that standard tests miss. The DnD assay amplifies subtle phenotypes by controlling growth-delay dynamics and antibiotic exposure, enabling earlier detection of resistance variants and tolerance states. If adopted by clinical microbiology labs and CROs, the DnD approach could change empirical therapy decisions, speed identification of emerging resistance mechanisms and support antibiotic-development pipelines by improving preclinical screening sensitivity.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.